CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES
A method of treating cancer in a subject is disclosed. The method comprises administering to the subject: (i) a therapeutically effective amount of an inhibitory agent that down-regulates an amount of a polypeptide selected from the group consisting of BCL-2, MCL-1 and cyclin D1; and (ii) a therapeutically effective amount of a CXCR4 binding agent that increases the expression of miR-15a and/or 16-1, thereby treating the cancer.
1 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject:
(i) a therapeutically effective amount of an inhibitory agent that down-regulates an amount of a polypeptide selected from the group consisting of BCL-2, MCL-1 and cyclin D1; and
(ii) a therapeutically effective amount of a CXCR4 binding agent that increases the expression of miR-15a and/or 16-1, thereby treating cancer.
2 - 7 . (canceled)
8 . The method of claim 1 , wherein said inhibitory agent is a BCl-2 antagonist.
9 . The method of claim 8 , wherein said BCl-2 antagonist is selected from the group consisting of Oblimersen, SPC-2996, RTA-402, Gossypol, AT-101, Obatoclax mesylate, A-371191, A-385358, A-438744, ABT-737, ABT-199, AT-101, BL-11, BL-193, GX-15-003, 2-Methoxyantimycin A3, HA-14-1, KF-67544, Purpurogallin, TP-TW-37, YC-137 and Z-24.
10 . The method of claim 9 , wherein said BCl-2 antagonist is ABT-199.
11 . The method of claim 1 , further comprising an additional chemotherapeutic agent.
12 . The method of claim 11 , wherein said additional chemotherapeutic agent is rituximab and Bendamastin.
13 . The method of claim 1 , wherein said CXCR4 binding agent binds to the CXCL12 binding site of CXCR4.
14 . The method of claim 1 , wherein said agent is BL8040.
15 . The method of claim 1 , wherein said CXCR4 binding agent is gp120 or CXCL-12.
16 - 17 . (canceled)
18 . A method of rendering a BCl-2 antagonist resistant subject more susceptible to treatment with a BCl-2 antagonist, the method comprising administering to the subject: a CXCR4 binding agent that increases the expression of miR-15a and/or 16 in the subject.
19 . The method of claim 18 , wherein said BCl-2 antagonist is selected from the group consisting of Oblimersen, SPC-2996, RTA-402, Gossypol, AT-101, Obatoclax mesylate, A-371191, A-385358, A-438744, ABT-737, ABT-199, AT-101, BL-11, BL-193, GX-15-003, 2-Methoxyantimycin A3, HA-14-1, KF-67544, Purpurogallin, TP-TW-37, YC-137 and Z-24.
20 . The method of claim 18 , wherein said BCl-2 antagonist is ABT-199.
21 . The method of claim 18 , wherein said CXCR4 binding agent binds to the CXCL12 binding site of CXCR4.
22 . The method of claim 18 , wherein said CXCR4 binding agent is BL8040.
23 . The method of claim 18 , wherein said CXCR4 binding agent is gp120 or CXCL-12.
24 . The method of claim 18 , wherein the subject has a cancer selected from the group consisting of a hematological cancer, neuroblastoma, retinoblastoma bladder cancer, esophageal carcinoma, sarcomas, colorectal cancer, melanoma, parathyroid adenoma and breast cancer.
25 . The method of claim 24 , wherein said hematological cancer is selected from the group consisting of of Chronic Myelogenous Leukemia (CML), CML accelerated phase, or blast crisis, multiple myeloma, Hypereosinophilic Syndrome (HES), myelodysplastic syndrome (MDS), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic neutrophilic leukemia (CNL), acute undifferentiated leukemia (AUL), anaplastic large-cell lymphoma (ALCL), prolymphocytic leukemia (PML), juvenile myelomonocyctic leukemia (JMML), adult T-cell ALL, AML with trilineage myelodysplasia (AML/TMDS), mixed lineage leukemia (MLL), myeloproliferative disorders (MPD), multiple myeloma, (MM) and myeloid sarcoma.
26 . A method of treating cancer or a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of gp120 or CXCL12, thereby treating cancer or neurodegenerative disease, with the proviso that the cancer is not prostate cancer.
27 . The method of claim 26 , wherein the cancer is a hematological cancer.
28 . The method of claim 26 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease (AD), Parkinson's disease, and frontotemporal dementias (FTD).
29 - 33 . (canceled)
34 . A method of treating HIV in a subject the method comprising administering to the subject a polynucleotide agent which is complementary to a nucleotide sequence of human miR-15a and/or 16-1, thereby treating HIV in a subject.